Content Validity of HIT‐6 as a Measure of Headache Impact in People With Migraine: A Narrative Review

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

(2018) David W. Dodick et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Migraine is first cause of disability in under 50s: will health politicians now take notice?

(2018) Timothy J. Steiner et al.   JOURNAL OF HEADACHE AND PAIN

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

(2018) Andrew M. Blumenfeld et al.   JOURNAL OF HEADACHE AND PAIN

Migraine and risk of cardiovascular diseases: Danish population based matched cohort study

(2018) Kasper Adelborg et al.   BMJ-British Medical Journal

Migraine and risk of cardiovascular diseases: Danish population based matched cohort study

(2018) Kasper Adelborg et al.   BMJ-British Medical Journal

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

(2018)   HEADACHE

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale

(2017) Richard B. Lipton et al.   HEADACHE

Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID)

(2017) Asha Hareendran et al.   Health and Quality of Life Outcomes

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis

(2017) Manjit Matharu et al.   JOURNAL OF HEADACHE AND PAIN

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

Erenumab (AMG 334) in episodic migraine

(2017) Messoud Ashina et al.   NEUROLOGY

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program

(2016) Richard B Lipton et al.   CEPHALALGIA

Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches

(2016) Sally Mannix et al.   Health and Quality of Life Outcomes

Migraine and its psychiatric comorbidities

(2016) Mia Tova Minen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Migraine and risk of cardiovascular disease in women: prospective cohort study

(2016) Tobias Kurth et al.   BMJ-British Medical Journal

Migraine and risk of cardiovascular disease in women: prospective cohort study

(2016) Tobias Kurth et al.   BMJ-British Medical Journal

Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial

(2015) Charly Gaul et al.   JOURNAL OF HEADACHE AND PAIN

Development of the Headache Activities of Daily Living Index: Initial Validity Study

(2015) Howard Vernon et al.   JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS

The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results

(2014) Aubrey Manack Adams et al.   CEPHALALGIA

Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine

(2014) Regina Rendas-Baum et al.   Health and Quality of Life Outcomes

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program

(2013) S. K. Aurora et al.   ACTA NEUROLOGICA SCANDINAVICA

What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients

(2013) Antonia FH Smelt et al.   CEPHALALGIA

Minimal clinically important change on the Headache Impact Test-6 questionnaire in patients with chronic tension-type headache

(2012) René F Castien et al.   CEPHALALGIA

The Development of a Survey to Measure Completeness of Response to Migraine Therapy

(2012) Cheryl D. Coon et al.   HEADACHE

The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients

(2012) Regina Rendas-Baum et al.   QUALITY OF LIFE RESEARCH

Validity and Reliability of the Migraine-Treatment Optimization Questionnaire

(2009) RB Lipton et al.   CEPHALALGIA

Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment

(2008) M. E. Bigal et al.   NEUROLOGY